QNRX

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

Feb 26, 2026

Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASHBURN, Va., Feb. 26, 2026 - PRISM MediaWire (Press Release Service – Press Release Distribution) - In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) today highlighted the continued growth of its NETHERTON NOW awareness campaign, which seeks to amplify the voices of patients, caregivers and clinicians impacted by Netherton Syndrome, a rare genetic disease...

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Jan 7, 2025

Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003 New York, January 07, 2024 -PRISM MediaWire - PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company’s notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet...

NEWSROOM

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Contact Us